Appointment of Dr Sally Bennett to the
Supervisory Board
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq:
IPHA) (“Innate” or the “Company”) announced the
voting results of its shareholders at the Annual General Meeting
(“AGM”), which took place on May 20, 2022, in Marseille. All
resolutions were voted on in accordance with the Executive Board’s
recommendations.
A total of 134 votes were cast out of a total of 32,598,725
shares giving right to 33,088,040 voting rights, representing a
quorum of 40.88%.
The resolutions, the results of the votes and other documents
relating to the AGM along with the AGM recording will be available
in the Annual General Meeting 2022 section of the Company’s
website.
The Company’s 2021 20-F is available on the Investors section of
the website.
As part of the resolutions voted by shareholders, Dr Sally
Bennett was appointed as new member of the Supervisory Board. She
was appointed as a member of the Audit Committee during the
Supervisory Board Meeting of May 20, 2022.
“We are very pleased to welcome Dr Sally Bennett as new
Supervisory Board member of Innate Pharma,” said Hervé Brailly,
Chairman of the Supervisory Board of Innate Pharma. “Her deep
experience in finance and her extensive knowledge of healthcare and
capital markets will be an asset to the Company. As Innate
continues to execute on its strategy, we are committed to regularly
evolve our Board's composition to ensure we have the right mix of
skills and experience to advance our goals and reflect the diverse
views of Innate's shareholders.”
Dr. Sally Bennett has over 20 years of experience in financial
analysis and capital markets in the life sciences and
biopharmaceutical industry. She is currently a senior member of the
private investment team (part-time) at HealthCor, a large
healthcare focused US based investment firm where she previously
managed the public biopharmaceuticals investment portfolio and
currently co-leads the funds more recent move into private
investing. She is a member of the Institute of Directors (IoD) and
has achieved CertIoD qualification. Dr. Bennett holds a Bachelor of
Science in Anatomy and a Medical Degree, both with honors, from the
University of Manchester.
Today, Mr Patrick Langlois decided to resign from its mandate of
Supervisory Board member of Innate Pharma.
"Patrick has been a valued member of the Supervisory Board and
we are grateful for his important contribution over the past twelve
years. On behalf of the Supervisory Board, I would like to thank
him for his commitment over the years and wish him all the best for
the future,” said Hervé Brailly.
To date, the Supervisory Board of Innate Pharma is composed
of:
- Hervé Brailly,
Chairman
- Irina Staatz-Granzer,
Vice-Chairman
- Sally Bennett
- Jean-Yves Blay
- Pascale Boissel
- Gilles Brisson
- Véronique
Chabernaud
- Bpifrance Participations,
represented by Olivier Martinez
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage oncology-focused
biotech company dedicated to improving treatment and clinical
outcomes for patients through therapeutic antibodies that harness
the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several
potentially first-in-class clinical and preclinical candidates in
cancers with high unmet medical need.
Innate is a pioneer in the understanding of natural killer cell
biology and has expanded its expertise in the tumor
microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France, with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com.
Information about Innate Pharma shares:
ISIN code
FR0010331421
Ticker code
Euronext: IPH Nasdaq: IPHA
LEI
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors:
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995.The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts, the Company’s continued
ability to raise capital to fund its development and the overall
impact of the COVID-19 outbreak on the global healthcare system as
well as the Company’s business, financial condition and results of
operations. For an additional discussion of risks and uncertainties
which could cause the company's actual results, financial
condition, performance or achievements to differ from those
contained in the forward-looking statements, please refer to the
Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2021, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public, by
the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220520005388/en/
Investors and Media
Innate Pharma Henry Wheeler +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
ATCG Press Marie Puvieux (France) +33 981 87 46 72
innate-pharma@atcg-partners.com
Innate Pharma (EU:IPH)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
Von Mär 2023 bis Mär 2024